These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 21706156)

  • 1. MDM2 SNP309 and TP53 R72P associated with severe and febrile neutropenia in breast cancer patients treated with 5-FU/epirubicin/cyclophosphamide.
    Okishiro M; Kim SJ; Tsunashima R; Nakayama T; Shimazu K; Shimomura A; Maruyama N; Tamaki Y; Noguchi S
    Breast Cancer Res Treat; 2012 Apr; 132(3):947-53. PubMed ID: 21706156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients.
    Schmidt MK; Tommiska J; Broeks A; van Leeuwen FE; Van't Veer LJ; Pharoah PD; Easton DF; Shah M; Humphreys M; Dörk T; Reincke SA; Fagerholm R; Blomqvist C; Nevanlinna H
    Breast Cancer Res; 2009; 11(6):R89. PubMed ID: 20021639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of the germline TP53 R72P and MDM2 SNP309 variants with breast cancer survival in specific breast tumor subgroups.
    van den Broek AJ; Broeks A; Horlings HM; Canisius SV; Braaf LM; Langerød A; Van't Veer LJ; Schmidt MK
    Breast Cancer Res Treat; 2011 Nov; 130(2):599-608. PubMed ID: 21667122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Individual and combined effects of MDM2 SNP309 and TP53 Arg72Pro on breast cancer risk: an updated meta-analysis.
    Cheng H; Ma B; Jiang R; Wang W; Guo H; Shen N; Li D; Zhao Q; Wang R; Yi P; Zhao Y; Liu Z; Huang T
    Mol Biol Rep; 2012 Sep; 39(9):9265-74. PubMed ID: 22729912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MDM2 SNP309 T>G alone or in combination with the TP53 R72P polymorphism does not appear to influence disease expression and age of diagnosis of colorectal cancer in HNPCC patients.
    Talseth BA; Meldrum C; Suchy J; Kurzawski G; Lubinski J; Scott RJ
    Int J Cancer; 2007 Feb; 120(3):563-5. PubMed ID: 17096342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors.
    Idbaih A; Boisselier B; Marie Y; Sanson M; El Hallani S; Crinière E; Fourtassi M; Paris S; Carpentier C; Rousseau A; Mokhtari K; Combadière C; Laigle-Donadey F; Hoang-Xuan K; Delattre JY
    Brain Res; 2008 Mar; 1198():16-20. PubMed ID: 18262501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MDM2 rs2279744 and TP53 rs1042522 polymorphisms associated with etoposide- and cisplatin-induced grade III/IV neutropenia in Chinese extensive-stage small-cell lung cancer patients.
    Wang X; Wang YZ; Ma KW; Chen X; Li W
    Oncol Res Treat; 2014; 37(4):176-80. PubMed ID: 24732641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TP53 mutations and MDM2(SNP309) identify subgroups of AML patients with impaired outcome.
    Falk IJ; Willander K; Chaireti R; Lund J; Nahi H; Hermanson M; Gréen H; Lotfi K; Söderkvist P
    Eur J Haematol; 2015 Apr; 94(4):355-62. PubMed ID: 25156865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined effects of MDM2 SNP309 and TP53 R72P polymorphisms, and soy isoflavones on breast cancer risk among Chinese women in Singapore.
    Koh WP; Van Den Berg D; Jin A; Wang R; Yuan JM; Yu MC
    Breast Cancer Res Treat; 2011 Dec; 130(3):1011-9. PubMed ID: 21833626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TP53 R72P and MDM2 SNP309 polymorphisms in modification of childhood acute lymphoblastic leukemia susceptibility.
    Do TN; Ucisik-Akkaya E; Davis CF; Morrison BA; Dorak MT
    Cancer Genet Cytogenet; 2009 Nov; 195(1):31-6. PubMed ID: 19837266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of p53 R72P polymorphism in the association of MDM2-SNP309 with breast cancer.
    Leu JD; Wang CY; Tsai HY; Lin IF; Chen RC; Lee YJ
    Oncol Rep; 2011 Jun; 25(6):1755-63. PubMed ID: 21479369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL.
    Dong HJ; Fang C; Fan L; Zhu DX; Wang DM; Zhu HY; Zhuang Y; Miao KR; Liu P; Xu W; Li JY
    Int J Cancer; 2012 May; 130(9):2054-61. PubMed ID: 21647873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TP53 and MDM2 gene polymorphisms, gene-gene interaction, and hepatocellular carcinoma risk: evidence from an updated meta-analysis.
    Peng Q; Lao X; Chen Z; Lai H; Deng Y; Wang J; Mo C; Sui J; Wu J; Zhai L; Yang S; Qin X; Li S
    PLoS One; 2013; 8(12):e82773. PubMed ID: 24376578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of breast cancer outcome with status of p53 and MDM2 SNP309.
    Boersma BJ; Howe TM; Goodman JE; Yfantis HG; Lee DH; Chanock SJ; Ambs S
    J Natl Cancer Inst; 2006 Jul; 98(13):911-9. PubMed ID: 16818855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium.
    Schmidt MK; Reincke S; Broeks A; Braaf LM; Hogervorst FB; Tollenaar RA; Johnson N; Fletcher O; Peto J; Tommiska J; Blomqvist C; Nevanlinna HA; Healey CS; Dunning AM; Pharoah PD; Easton DF; Dörk T; Van't Veer LJ;
    Cancer Res; 2007 Oct; 67(19):9584-90. PubMed ID: 17909070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel.
    Chrisanthar R; Knappskog S; Løkkevik E; Anker G; Ostenstad B; Lundgren S; Risberg T; Mjaaland I; Skjønsberg G; Aas T; Schlichting E; Fjösne HE; Nysted A; Lillehaug JR; Lønning PE
    PLoS One; 2011 Apr; 6(4):e19249. PubMed ID: 21556366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetic association between GSTP1 genetic polymorphism and febrile neutropenia in Japanese patients with early breast cancer.
    Sugishita M; Imai T; Kikumori T; Mitsuma A; Shimokata T; Shibata T; Morita S; Inada-Inoue M; Sawaki M; Hasegawa Y; Ando Y
    Breast Cancer; 2016 Mar; 23(2):195-201. PubMed ID: 25008867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Febrile neutropenia incidence and hematological toxicity with the FEC100-docetaxel regimen in the treatment of early-stage breast cancer.
    Cousin S; Le Rhun E; Mailliez A; Fournier C; Bonneterre J
    Bull Cancer; 2012; 99(7-8):75-80. PubMed ID: 22713627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC).
    Vulsteke C; Lambrechts D; Dieudonné A; Hatse S; Brouwers B; van Brussel T; Neven P; Belmans A; Schöffski P; Paridaens R; Wildiers H
    Ann Oncol; 2013 Jun; 24(6):1513-25. PubMed ID: 23396606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of TP53 Pro72Arg and MDM2 SNP285-SNP309 polymorphisms in an Italian cohort of LFS suggestive patients lacking identifiable TP53 germline mutations.
    Ponti F; Corsini S; Gnoli M; Pedrini E; Mordenti M; Sangiorgi L
    Fam Cancer; 2016 Oct; 15(4):635-43. PubMed ID: 26956143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.